Amgen
Nasdaq: AMGN · Health Care · Biotechnology · THOUSAND OAKS, CA
Biotech company selling bone, cardiovascular, oncology and inflammation medicines (Prolia, Repatha, Tezspire) and rare-disease drugs from Horizon.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Net income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| EPS — diluted | $10.28 per share | $12.11 per share | $12.49 per share | $7.56 per share | $14.23 per share |
| Cash from operations | $9.3B | $9.7B | $8.5B | $11.5B | $10.0B |
| Free cash flow | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| Total assets | $61.2B | $65.1B | $97.2B | $91.8B | $90.6B |
Recent filings
Members see much more
The full AMGN file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence